Bridgebio Pharma Stock Performance
| BBIO Stock | USD 72.29 4.24 6.23% |
BridgeBio Pharma has a performance score of 4 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.39, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BridgeBio Pharma will likely underperform. BridgeBio Pharma right now shows a risk of 3.03%. Please confirm BridgeBio Pharma jensen alpha, semi variance, day typical price, as well as the relationship between the maximum drawdown and accumulation distribution , to decide if BridgeBio Pharma will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in BridgeBio Pharma are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very weak forward indicators, BridgeBio Pharma may actually be approaching a critical reversion point that can send shares even higher in March 2026. ...more
Actual Historical Performance (%)
One Day Return 6.78 | Five Day Return (10.99) | Year To Date Return (13.02) | Ten Year Return 147.01 | All Time Return 147.01 |
1 | Disposition of 25484 shares by Valantine Hannah of BridgeBio Pharma at 66.07 subject to Rule 16b-3 | 11/12/2025 |
2 | 10 Health Care Stocks With Whale Alerts In Todays Session | 11/14/2025 |
3 | Disposition of 6956 shares by Thomas Trimarchi of BridgeBio Pharma at 66.8398 subject to Rule 16b-3 | 11/17/2025 |
4 | Disposition of 5708 shares by Neil Kumar of BridgeBio Pharma at 74.7966 subject to Rule 16b-3 | 12/04/2025 |
5 | BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference | 01/12/2026 |
6 | BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible ... | 01/14/2026 |
7 | BridgeBio Prices Offering of 550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 | 01/16/2026 |
8 | Analysts Remain Positive on BridgeBio Pharma, Inc. After Strong 2025 Results | 01/20/2026 |
9 | Wells Fargo Remains a Buy on BridgeBio Pharma | 01/23/2026 |
10 | BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635 | 01/27/2026 |
11 | BridgeBio Pharma Now Covered by Analysts at Barclays | 01/28/2026 |
12 | Acquisition by Neil Kumar of 11554 shares of BridgeBio Pharma subject to Rule 16b-3 | 02/02/2026 |
13 | Y Intercept Hong Kong Ltd Has 724,000 Stock Holdings in BridgeBio Pharma, Inc. BBIO - MarketBeat | 02/03/2026 |
| Begin Period Cash Flow | 394.7 M | |
| Total Cashflows From Investing Activities | 60.8 M |
BridgeBio | Build AI portfolio with BridgeBio Stock |
BridgeBio Pharma Relative Risk vs. Return Landscape
If you would invest 6,658 in BridgeBio Pharma on November 11, 2025 and sell it today you would earn a total of 571.00 from holding BridgeBio Pharma or generate 8.58% return on investment over 90 days. BridgeBio Pharma is currently generating 0.1799% in daily expected returns and assumes 3.0309% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than BridgeBio, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BridgeBio Pharma Target Price Odds to finish over Current Price
The tendency of BridgeBio Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 72.29 | 90 days | 72.29 | about 53.17 |
Based on a normal probability distribution, the odds of BridgeBio Pharma to move above the current price in 90 days from now is about 53.17 (This BridgeBio Pharma probability density function shows the probability of BridgeBio Stock to fall within a particular range of prices over 90 days) .
BridgeBio Pharma Price Density |
| Price |
Predictive Modules for BridgeBio Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BridgeBio Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.BridgeBio Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. BridgeBio Pharma is not an exception. The market had few large corrections towards the BridgeBio Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BridgeBio Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BridgeBio Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.07 | |
β | Beta against Dow Jones | 1.39 | |
σ | Overall volatility | 5.28 | |
Ir | Information ratio | 0.03 |
BridgeBio Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BridgeBio Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BridgeBio Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| BridgeBio Pharma had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 221.9 M. Net Loss for the year was (543.35 M) with profit before overhead, payroll, taxes, and interest of 338.84 M. | |
| BridgeBio Pharma currently holds about 715.71 M in cash with (520.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.83. | |
| Over 95.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Y Intercept Hong Kong Ltd Has 724,000 Stock Holdings in BridgeBio Pharma, Inc. BBIO - MarketBeat |
BridgeBio Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of BridgeBio Stock often depends not only on the future outlook of the current and potential BridgeBio Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. BridgeBio Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 186.1 M | |
| Cash And Short Term Investments | 681.1 M |
BridgeBio Pharma Fundamentals Growth
BridgeBio Stock prices reflect investors' perceptions of the future prospects and financial health of BridgeBio Pharma, and BridgeBio Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BridgeBio Stock performance.
| Return On Equity | -17.9 | ||||
| Return On Asset | -0.43 | ||||
| Profit Margin | (2.25) % | ||||
| Operating Margin | (1.13) % | ||||
| Current Valuation | 14.25 B | ||||
| Shares Outstanding | 191.63 M | ||||
| Price To Earning | (13.72) X | ||||
| Price To Book | 123.68 X | ||||
| Price To Sales | 36.86 X | ||||
| Revenue | 221.9 M | ||||
| Gross Profit | 338.84 M | ||||
| EBITDA | (436.83 M) | ||||
| Net Income | (543.35 M) | ||||
| Cash And Equivalents | 715.71 M | ||||
| Cash Per Share | 4.83 X | ||||
| Total Debt | 1.73 B | ||||
| Debt To Equity | 4.61 % | ||||
| Current Ratio | 5.46 X | ||||
| Book Value Per Share | (10.04) X | ||||
| Cash Flow From Operations | (520.73 M) | ||||
| Earnings Per Share | (4.21) X | ||||
| Market Capitalization | 13.04 B | ||||
| Total Asset | 919.34 M | ||||
| Retained Earnings | (3.1 B) | ||||
| Working Capital | 566.29 M | ||||
| Current Asset | 513.67 M | ||||
| Current Liabilities | 51.37 M | ||||
About BridgeBio Pharma Performance
By examining BridgeBio Pharma's fundamental ratios, stakeholders can obtain critical insights into BridgeBio Pharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that BridgeBio Pharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.69) | (0.72) | |
| Return On Capital Employed | (0.89) | (0.94) | |
| Return On Assets | (0.67) | (0.70) | |
| Return On Equity | 0.33 | 0.34 |
Things to note about BridgeBio Pharma performance evaluation
Checking the ongoing alerts about BridgeBio Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BridgeBio Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BridgeBio Pharma had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 221.9 M. Net Loss for the year was (543.35 M) with profit before overhead, payroll, taxes, and interest of 338.84 M. | |
| BridgeBio Pharma currently holds about 715.71 M in cash with (520.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.83. | |
| Over 95.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Y Intercept Hong Kong Ltd Has 724,000 Stock Holdings in BridgeBio Pharma, Inc. BBIO - MarketBeat |
- Analyzing BridgeBio Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BridgeBio Pharma's stock is overvalued or undervalued compared to its peers.
- Examining BridgeBio Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BridgeBio Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BridgeBio Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BridgeBio Pharma's stock. These opinions can provide insight into BridgeBio Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Will Biotechnology sector continue expanding? Could BridgeBio diversify its offerings? Factors like these will boost the valuation of BridgeBio Pharma. Projected growth potential of BridgeBio fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every BridgeBio Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.21) | Revenue Per Share | Quarterly Revenue Growth 43.18 | Return On Assets | Return On Equity |
BridgeBio Pharma's market price often diverges from its book value, the accounting figure shown on BridgeBio's balance sheet. Smart investors calculate BridgeBio Pharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since BridgeBio Pharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between BridgeBio Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BridgeBio Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.